Iridex Corp. v. Synergetics, Inc.

478 F. Supp. 2d 1146, 2007 U.S. Dist. LEXIS 16986, 2007 WL 776120
District Court, E.D. Missouri·Decided March 9, 2007·No. 4:05CV1916 CDP·Published

Opinion

478 F.Supp.2d 1146 (2007)

IRIDEX CORPORAITON, Plaintiff
v.
SYNERGETICS, INC., Defendant.

No. 4:05CV1916 CDP.

United States District Court, E.D. Missouri, Eastern Division.

March 9, 2007.

*1147 David M. Alban, James Pooley, Katherine Nolan-Stevaux, L. Scott Oliver, Marc David Peters Pooley And Oliver, LLP, Palo Alto, CA, Mcpherson Dorsett Moore, Ned W. Randle, William B. Cuhningham, Jr., Polster and Lieder, St. Louis, MO, for Plaintiff.

Kara R. Yancey, Matthew L. Cutler, Rudolph A. Telscher, Jr., Molly B. Edwards, Harness and Dickey, St. Louis, MO, for Defendant.

MEMORANDUM AND ORDER

CATHERINE D. PERRY, United States District Judge.

This opinion deals with the parties' cross-motions for summary judgment on Synergetics' invalidity defenses. Synergetics argues that Iridex's '492 patent fails to meet the written description and enablement requirements of 35 U.S.C. § 112 and that the patent is anticipated by the Laserscope patent. Alternatively, it argues that the patent is obvious in light of Laserscope and other prior art. I conclude from the undisputed evidence that Iridex is entitled to judgment as a matter of law on Synergetics' defenses under the written description and enablement requirements. I also conclude that the undisputed evidence shows that the Laserscope patent does not contain all of the elements of the patent in suit, so the 492 patent is not invalid for anticipation. I conclude that factual issues remain that preclude a summary determination of the obviousness defense.

I. Written Description/Enablement

Under 35 U.S.C. § 112, a patent must include a written description "of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same." This provision contains "two closely related requirements." LizardTech, Inc. v. Earth Resource Mapping, Inc., 424 F.3d 1336, 1344 (Fed.Cir.2005). The first is *1148 that the written description must allow a person of ordinary skill in the art to know that the inventor possessed the invention, and the other is that the description must be sufficient to enable such a person to make the invention without undue experimentation. Id. at 1344-45. The written description requirement prevents "an applicant from later asserting that he invented that which he did not." Pandrol USA, LP v. Airboss Ry. Prods., Inc., 424 F.3d 1161, 1165 (Fed.Cir.2005) (citation omitted). The issue is whether the specifications adequately support the breadth of all the claims that are presented, and this determination is made on a claim by claim basis. Capon v. Eshhar, 418 F.3d 1349, 1360 (Fed.Cir.2005).

For its argument that the specification fails to provide notice to one skilled in the art that Iridex possessed the invention at the time of the '492 patent, Synergetics does not point to any particular claim that is not adequately supported by the patent specification. Instead, Synergetics argues with the court's claims construction and argues that if the claims are broad enough to cover the Synergetics products, they must be invalid. The vagueness of this argument shows the problem Synergetics has: it cannot point to any claim that is broader than the specification, and therefore this § 112 argument must fail. Synergetics also argues that § 112 requires the claims to be limited to the one embodiment shown in the specification, but this again is not the law. Nothing in § 112 requires the specifications to describe all possible embodiments: "A claim will not be invalidated on section 112 grounds simply because the embodiments of the specification do not contain examples explicitly covering the full scope of the claim language." LizardTech, 424 F.3d at 1345. Finally, to the extent that Synergetics attempts to argue that Iridex's patent must be narrowed under § 112 because Iridex criticized Synergetics' products, this argument fails because the statements were made years after the patent was obtained. This is a far different case from Honeywell International, Inc. v. ITT Industries, Inc., 452 F.3d 1312 (Fed.Cir. 2006), on which Synergetics relies, because in Honeywell the supposedly limiting statements were made during the prosecution of the patent. Additionally, of course, Iridex's statements compared Synergetics' product to Iridex's product, not to Iridex's patent. The undisputed evidence shows that a person of skill in the art would know from the patent what Iridex had invented.

Synergetics' lack of enablement argument relies largely on its own unsupported statements about how hard it was for it to invent its infringing products. The evidence it presented on this point simply shows that it spent several years seeking to improve its own product, which, as Iridex correctly points out, only goes to show that it was experimenting in an attempt to make a commercially successful product. That is not the test of enablement. Enablement "does not turn on whether the accused product is enabled. Rather, to be enabling, the specification of the patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation." Durel Corp. v. Osram Sylvania Inc., 256 F.3d 1298, 1306 (Fed. Cir.2001) (internal quotation omitted).

Synergetics relies on a conclusory affidavit of its president, who stated that Synergetics "invested an enormous amount of time and energy in research and development." This is hardly convincing evidence. Much more persuasive on the written description and enablement defenses is the deposition testimony of Michael Auld, a Synergetics employee, who testified that he was able to create the Synergetics product even without having an Iridex laser because, "luckily, the Kelsoe patent *1149 does a good, job of teaching the system itself, right, so you can just read the patent and understand the — you know, the mechanics of what's going on there." Auld deposition, page 16, lines 5-8. Synergetics has presented nothing that would support a § 112 defense, and Iridex is entitled to summary judgment on these defenses.

II. Anticipation by Laserscope

Synergetics argues that the '492 patent is invalid because it is fully anticipated by the Laserscope patent. Under 35 U.S.0 § 102(a), a person "is not entitled to a patent if the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country." Anticipation is a question of fact, but summary judgment may be appropriate where there is no genuine issue of material fact. Medical Instrumentation & Diagnostics Corp. v. Elekta AB, 344 F.3d 1205, 1220 (Fed.Cir. 2003)

Free access — add to your briefcase to read the full text and ask questions with AI

Iridex Corp. v. Synergetics, Inc., 478 F. Supp. 2d 1146, 2007 U.S. Dist. LEXIS 16986, 2007 WL 776120 (E.D. Mo. 2007).

478 F. Supp. 2d 1146 (Iridex Corp. v. Synergetics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related